- Home
- CRWD vs ABBV Comparison
CRWD vs ABBV Comparison
Compare CRWD & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRWD | ABBV |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.5B | 358.5B |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CRWD | ABBV |
|---|---|---|
| Price | $681.08 | $222.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 48 | 18 |
| Target Price | ★ $507.00 | $253.71 |
| AVG Volume (30 Days) | 3.5M | ★ 3.6M |
| Earning Date | 06-02-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.11 | ★ 0.39 |
| Revenue | $4,812,005,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $24.85 | $11.87 |
| Revenue Next Year | $21.40 | $8.12 |
| P/E Ratio | $6,263.64 | ★ $568.14 |
| Revenue Growth | ★ 21.71 | 8.57 |
| 52 Week Low | $342.72 | $181.75 |
| 52 Week High | $785.66 | $244.81 |
Technical Indicators
Market Signals| Indicator | CRWD | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 56.12 |
| Support Level | $463.35 | $220.11 |
| Resistance Level | $785.66 | $230.91 |
| Average True Range (ATR) | 38.24 | 5.03 |
| MACD | -10.72 | 0.06 |
| Stochastic Oscillator | 39.03 | 61.92 |
Price Performance
Historical ComparisonAbout CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.